Tobramycin

Binds to 30S ribosomal subunit, inhibiting protein synthesis

• ·Prosthetic-joint Infection
• ·Knee Infection
• ·Arthroplasty Complications
• ·Joint Infection
• ·Arthroplasty, Replacement, Knee

Typical dose

[object Object] mg every 24 h

Intravenous

Therapeutic range

0–2 mg/L

Trough

Peak range

6–10 mg/L

Steady state

~12 hours

Re-check

At least twice weekly

• Trough: before next dose
• Peak: 30 min after infusion end

No curated interaction pairs are recorded for Tobramycin. This is not a statement that none exist — check a full interaction reference before combining.

• Nephrotoxicity
• Ototoxicity
• Vestibular toxicity
• Neuromuscular blockade

Half-life

2-3 hours

Protein binding

<30%

Clearance

4.5 L/h

adult patients

Volume of distribution

18 L

Renally eliminated

95%

Dose review in renal impairment

Model

2-compartment

Not recorded for Tobramycin. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.